Working... Menu

Evaluation of Renastep (Renastep)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03602937
Recruitment Status : Recruiting
First Posted : July 27, 2018
Last Update Posted : July 27, 2018
Information provided by (Responsible Party):
Vitaflo International, Ltd

Brief Summary:

Evaluation of Renastep is a 28-day long, prospective nutritional study that will recruit 15 patients aged between 3 and 18 years of age with Chronic Kidney Disease. Participants will incorporate Renastep into their renal specific diet, during which time they will record gastrointestinal symptoms, adherence to recommended intakes and thoughts on its palatability. A Baseline CRF completed by the Investigator at the start of the trial will record demographic information, GI history and the most recent renal bio-marker results. Bio-marker results recorded as part of routine care over the course of the study will be captured in the End of Study CRF.

The study is designed to generate acceptability data that will be used to support an application to the Advisory Committee on Borderline Substances for Renastep to be reimbursable on prescription within the NHS.

Condition or disease Intervention/treatment Phase
Chronic Kidney Diseases Renal Disease Dietary Supplement: Renastep Not Applicable

Detailed Description:

Renastep is designed for use in the dietary management of kidney disease between 3 and 18 years of age. It is a high-energy liquid feed containing protein, carbohydrate, fat, vitamins, minerals, trace elements and DHA. It contains low levels of potassium, phosphorus, calcium, chloride and vitamin A compared with a standard paediatric enteral feed.

Vitaflo (International) Ltd has developed Renastep following a request from the Paediatric Renal Interest Nutrition Group (PRING). They requested a low potassium and phosphate, high energy liquid feed for the dietary management of children with kidney disease that can be used as a sip feed or as a part of a modular tube feed.

There is currently no product designed specifically for use in this age group. Current dietetic practice involves either prescribing a powdered infant formula, in variable concentrations, or manipulating an adult renal sip feed to construct a modular feed, meeting the particular individual requirements of a paediatric patient with chronic kidney disease. This can be time consuming, complicated, can frequently involve preparation error leading to over or underconcentration of key nutrients, and increases the risk of microbial contamination. As Renastep is a ready to use product designed specifically for children with kidney disease, it can be expected that it will be more easily incorporated into the dietary management of the patient than the current options available. This has also been requested by the children and their families. Renastep could replace unsafe current practices that are the only option available to clinicians.

In order for Renastep to be prescribed within the NHS, it must first be subject to an application to the Advisory Committee on Borderline Substances (ACBS). The ACBS require data on the product's acceptability, in terms of gastrointestinal tolerance, palatability and participants' adherence to recommended intakes. The ACBS require such acceptability studies to be conducted in at least 15 patients for whom the product is designed. This stipulation is the reason for conducting the trial within patients aged 3 - 18 years of age with Chronic Kidney Disease.

The study will last for 28 days. Participants will self-report study data in Daily Diary forms that include 7 days of gastrointestinal data, daily records of how much of the product has been taken compared to the amount prescribed and a final evaluation of the product's palatability. The investigator will complete a Baseline CRF at the first visit to record demographic information, GI history and the most recent urea, phosphorus and potassium results. This will be supplemented by an End of Study CRF which will record urea, phosphorus and potassium results recorded during the trial period as part of usual clinical care. Information relating to gastrointestinal tolerance of Renastep over the 28-day study period will also be recorded by the Investigator in the End of Study CRF.

All study data will be anonymised and reviewed by the local investigator prior to it being forwarded to the sponsor, Vitaflo (International) Ltd.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Open label prospective acceptability study.
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: A Study to Evaluate the Acceptability and Nutritional Suitability of Renastep, a Food for Special Medical Purposes (FSMP) for Use in the Dietary Management of Patients From 3-18 Years of Age With Chronic Kidney Disease (CKD)
Actual Study Start Date : April 17, 2018
Estimated Primary Completion Date : April 17, 2019
Estimated Study Completion Date : April 17, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Diseases

Arm Intervention/treatment
Experimental: Renastep
All participants to incorporate Renastep into their usual dietary regime.
Dietary Supplement: Renastep
Renastep is a ready-to-use, high energy, low volume liquid renal specific feed that can be administered enterally via tube or oral consumption.

Primary Outcome Measures :
  1. Patients' compliance with recommended intakes of Renastep. [ Time Frame: Days 1 - 28. ]
    Actual intake of the product will be compared with recommended intake. Participant to record how much of the product they took on each of the study days in a daily study dairy.

  2. Patients' gastrointestinal tolerance of Renastep. [ Time Frame: Days 1 - 7. ]
    Participant to record any gastrointestinal symptoms experienced in a daily study diary.

  3. Patients' thoughts on Renastep's palatability [ Time Frame: Day 28. ]
    Participants will rate Renastep's appearance, smell, taste, aftertaste, texture and presentation on a 5-point Likert scale at the end of their time on the study.

  4. Patients' thoughts on Renastep's ease of use [ Time Frame: Day 28. ]
    Participants will rate Renastep's ease of use on a 5-point likert scale at the end of their time on the study.

  5. Nutritional suitability [ Time Frame: Days 0 - 28 ]
    The product's nutritional suitability for use in a renal specific diet will be measured. The investigator will record the participant's most recent urea, phosphorus and potassium results (all mmo/L) taken as part of routine care prior to the intervention period beginning and all available results recorded as part of routine care over the course of the intervention period.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   3 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

i) Diagnosis of Chronic Kidney Disease.

ii) Aged between 3 and 18 years.

iii) Has a requirement for a restricted potassium and/or restricted phosphorus diet.

iv) Has a requirement for nutrition support.

v) Freely given, written, informed consent from patient or parent/guardian.

vi) Freely given, written assent (if appropriate).

Exclusion Criteria:

i) Inability to comply with the study protocol, in the opinion of the investigator.

ii) Aged under 3 years or over 18 years.

iii) Use of additional enteral feeds during the study period, unless clinically indicated and prescribed by the investigator (must be recorded in patient case record file).

iv) Women who are pregnant / breastfeeding at the start of the study or planning to become pregnant during the study period.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03602937

Layout table for location contacts
Contact: Joe Fahy 00441517099020 ext 241
Contact: Erika Brennan 00441517099020 ext 262

Layout table for location information
United Kingdom
Southampton Children's Hospital Recruiting
Southampton, Hampshire, United Kingdom, S016 6YD
Contact: Caroline Anderson    02380776072   
Contact: Natasha Chigbo    023 8120 5369   
Alder Hey Children's Hospital Recruiting
Liverpool, Merseyside, United Kingdom, L12 2AP
Contact: Alison Holmes    0151 525 5231   
Contact: Edward Staunton    0151 252 5570   
Birmingham Children's Hospital Recruiting
Birmingham, West Midlands, United Kingdom, B4 6NH
Contact: Sara Janes    0121 333 8803    Sara.Janes@BCH.NHS.UK   
Contact: Peter Price    0121 333 8748   
Sponsors and Collaborators
Vitaflo International, Ltd
Layout table for investigator information
Study Director: Caroline Anderson University Hospital Southampton NHS Foundation Trust
Principal Investigator: Alison Holmes Alder Hey Children's NHS Foundation Trust
Principal Investigator: Sara Janes Birmingham Women's and Children's NHS Foundation Trust

Layout table for additonal information
Responsible Party: Vitaflo International, Ltd Identifier: NCT03602937     History of Changes
Other Study ID Numbers: MCT-RENS-2017-11-07
First Posted: July 27, 2018    Key Record Dates
Last Update Posted: July 27, 2018
Last Verified: July 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Individual participant data will not be shared.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Vitaflo International, Ltd:
High energy, low volume
Low potassium
Low phosphorus
Low vitamin A

Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Renal Insufficiency, Chronic
Urologic Diseases
Renal Insufficiency